RobertTO'DonnellMD

PubMed

• 5 citations
  Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells.
  Jose Sandoval, Alexey Tomilov, Sandipan Datta, Sonia A. Allen, Robert T. O'Donnell, Thomas K. Sears, Kevin D. Woolard, Dmytro Kovalskyy, James M. Angelastro, Gino A Co...> ;Pharmaceuticals. 2020 Nov 24
• 10 citations
  A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia
  Benjamin Tomlinson, Joseph Tuscano, Mehrdad Abedi, Jeanna L Welborn, Mili Arora, Robert T. O'Donnell, Theodore Wun, Brian A. Jonas> ;American Journal of Hematology. 2019 Nov 1
• 11 citations
  A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
  Anthony B. El-Khoueiry, Robert T. O'Donnell, Thomas J. Semrad, Philip C. Mack, Suzette Blanchard, Nathan Bahary, Yixing Jiang, Yun Yen, John J. Wright, Helen X. Chen, ...> ;Cancer Chemotherapy and Pharmacology. 2018 Mar 8
• 8 citations
  A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation.
  Gustavo A. Barisone, Robert T. O'Donnell, Yunpeng Ma, Mastewal Abuhay, Kathleen Lundeberg, Sonia Gowda, Joseph Tuscano> ;Plos One. 2018 Jan 5
• 6 citations
  The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
  Mastewal Abuhay, Jason Kato, Emily Tuscano, Gustavo A. Barisone, Ranjit S. Sidhu, Robert T. O'Donnell, Joseph Tuscano> ;Cancer Immunology, Immunotherapy. 2016 Aug 9
• 3 citations
  Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
  YanGuo Kong, Gustavo A. Barisone, Ranjit S. Sidhu, Robert T. O'Donnell, Joseph Tuscano> ;Molecular Medicine. 2015 Aug 24
• 3 citations
  Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7
  YanGuo Kong, Gustavo A. Barisone, Mastewal Abuhay, Robert T. O'Donnell, Zaneb Buksh, Faraz Yousefian, Joseph Tuscano> ;Leukemia Research. 2014 Nov 1
• 63 citations
  Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
  Joseph Tuscano, Mrinal Dutia, Karen Chee, Ann Brunson, Christine Reed-Pease, Mehrdad Abedi, Jeanna L Welborn, Robert T. O'Donnell> ;British Journal of Haematology. 2014 May 1
• 23 citations
  Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute–Sponsored Trials
  Jeffrey S. Abrams, Margaret M. Mooney, James A. Zwiebel, Edward L. Korn, Steven H. Friedman, Shanda Finnigan, Patricia R. Schettino, Andrea Denicoff, Martha Kruhm, Mik...> ;Journal of the National Cancer Institute. 2013 Jul 3
• 59 citations
  Targeting CD22 in B-cell malignancies: current status and clinical outlook.
  Loretta Sullivan-Chang, Robert T. O'Donnell, Joseph Tuscano> ;Biodrugs. 2013 May 22
• 13 citations
  Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia
  Jason Kato, Noriko Satake, Robert T. O'Donnell, Mastewal Abuhay, Carly Lewis, Joseph Tuscano> ;Leukemia Research. 2013 Jan 1
• 12 citations
  Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma.
  Jason Kato, Robert T. O'Donnell, Mastewal Abuhay, Joseph Tuscano> ;Oncoimmunology. 2012 Dec 1
• 20 citations
  CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
  Joseph Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara, Robert T. O'Donnell> ;Cancer Research. 2012 Nov 1
• 38 citations
  Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.
  Jason Kato, Yuanpei Li, Kai Xiao, Joyce S Lee, Juntao Luo, Joseph Tuscano, Robert T. O'Donnell, Kit S. Lam> ;Molecular Pharmaceutics. 2012 May 1
• 5 citations
  The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
  Shiloh M. Martin, Eric Churchill, Hayes McKnight, Christopher M. Mahaffey, Yunpeng Ma, Robert T. O'Donnell, Joseph Tuscano> ;Journal of Hematology & Oncology. 2011 Dec 1
• 11 citations
  The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
  Joseph Tuscano, Yunpeng Ma, Shiloh M. Martin, Jason Kato, Robert T. O'Donnell> ;Cancer Immunology, Immunotherapy. 2011 Feb 24
• 17 citations
  Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).
  Robert T. O'Donnell, Shiloh M. Martin, Yunpeng Ma, William C. Zamboni, Joseph Tuscano> ;Investigational New Drugs. 2010 Jun 1
• 35 citations
  Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model
  Joseph Tuscano, Shiloh M. Martin, Yunpeng Ma, William C. Zamboni, Robert T. O'Donnell> ;Clinical Cancer Research. 2010 May 15
• 5 citations
  Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells.
  Robert T. O'Donnell, David Pearson, Hayes McKnight, Ya Peng Ma, Joseph Tuscano> ;Leukemia Research. 2009 Jul 1
• 7 citations
  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts
  Robert T. O'Donnell, Yunpeng Ma, Hayes McKnight, David Pearson, Joseph Tuscano> ;Cancer Immunology, Immunotherapy. 2009 May 13
• 7 citations
  Treatment of non-Hodgkin’s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy
  Robert T. O'Donnell, David Pearson, Hayes McKnight, Ya Peng Ma, Joseph Tuscano> ;Cancer Immunology, Immunotherapy. 2009 Mar 18
• 10 citations
  Imaging and Pharmacokinetics of 64Cu-DOTA-HB22.7 Administered by Intravenous, Intraperitoneal, or Subcutaneous Injection to Mice Bearing Non-Hodgkin’s Lymphoma Xenografts
  Shiloh M. Martin, Robert T. O'Donnell, David L. Kukis, Craig K. Abbey, Hayes McKnight, Julie L. Sutcliffe, Joseph Tuscano> ;Molecular Imaging and Biology. 2009 Mar 1
• 1 citations
  Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
  Orazio Schillaci, Gerald L. DeNardo, Sally J. DeNardo, Desiree S. Goldstein, Linda A. Kroger, Robert T. O'Donnell, Kathleen R. Lamborn> ;Cancer Biotherapy & Radiopharmaceuticals. 2007 Aug 1
• 198 citations
  Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.
  Thomas J. Semrad, Robert T. O'Donnell, Theodore Wun, Helen K. Chew, Danielle J Harvey, Hong Zhou, Richard H. White> ;Journal of Neurosurgery. 2007 Apr 1
• 2 citations
  Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer
  Joerg Lehmann, Gerald L. DeNardo, Aina Yuan, Sui Shen, Robert T. O'Donnell, Carol M. Richman, Sally J. DeNardo> ;International Journal of Radiation Oncology, Biology, Physics. 2006 Nov 15
• Join now to see all